|
Serratiopeptidase (Serratia E-15 protease, also known as serralysin, serrapeptase, serratiapeptase, serratia peptidase, serratio peptidase, or serrapeptidase) is a proteolytic enzyme (protease) produced by enterobacterium ''Serratia'' sp. E-15. This microorganism was originally isolated in the late 1960s from silkworm ''Bombyx mori'' L. (intestine),〔The preparation and some uses of the protease are described in . The enzyme was also described by and the strain of bacteria producing serratiopeptidase has been deposited with the American Type Culture Collection as strain ATCC 21074. (For online information about ATCC 21074, enter 21074 on (the ATCC/LGC search page ))〕 Serratiopeptidase is present in the silkworm intestine and allows the emerging moth to dissolve its cocoon. Serratiopeptase is produced by purification from culture of Serratia E-15 bacteria. ==Claims of anti-inflammatory benefits== Some alternative medicine proponents claim that serratiopeptidase is beneficial for pain and inflammation but "existing trials (been ) small and generally of poor methodological quality."〔 Online medical journal ''Bandolier'' (specializing in evidence-based thinking about healthcare)〔(Bandolier online home-page )〕 published an article (in about 2001) in response to a reader's enquiry about serratiopeptidase.〔The ''Bandolier'' article is undated and unsigned but the text indicates that it was written in response to a letter sent by a reader of a newspaper article that was published in 2001. No references later than 2001 are cited.〕 After searching PubMed and the Cochrane Library "to see if there are any randomised, controlled trials", the article stated that the "evidence on serratiopeptidase being effective for anything is not based on a firm foundation of clinical trials."〔(【引用サイトリンク】title=Serratiopeptidase: Finding the Evidence )〕 The search found 34 publications in the medical databases covered, that addressed the efficacy of serratiopeptidase, of which several were found to be animal experiments, personal letters, uncontrolled trials or those with inadequate or nonexistent randomisation. The article warned against ignoring safety issues with use of biological agents.〔 No studies were found to have been conducted on the efficacy of serratiopeptidase as treatment for back pain, heart attack, stroke, or asthma. Of the 10 medical conditions with randomized-evidence studies on file in connection with serratiopeptidase, the quality or construction of the trial studies was described as "generally poor".〔〔According to Bandolier: 〕 In a news article published Feb 22, 2011, Kyodo News reports: "Takeda Pharmaceutical Co. said Monday it will voluntarily recall an anti-inflammatory drug touted effective for a variety of conditions ranging from chronic bronchitis to sprained ankles because recent tests have cast doubt on its efficacy even though it has been on the market for more than 40 years. Double-blind experiments comparing the effects of the drug Danzen, which debuted in 1968, and placebos showed no significant differences between the two, the major drugmaker said. Sales of the product, generically called serrapeptase, totaled ¥6.7 billion in fiscal 2009, but the impact of the recall will likely be limited because similar drugs are being sold on the market, it said." 〔http://search.japantimes.co.jp/cgi-bin/nb20110222a5.html?〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Serratiopeptidase」の詳細全文を読む スポンサード リンク
|